The adult trial without diabetes reported a weight change of 18.7 percent with 7.2 mg, 15.6 percent with 2.4 mg, and 3.9 percent with placebo, across 72 weeks
This enzyme uses glutathione and requires selenium to work with harmful substances
The Phase 3 double-blind, randomized, placebo-controlled OASIS 3 trial also demonstrated reduced VMS at 12 weeks compared to placebo (primary endpoint) and the VMS reductions were maintained for up to 52 weeks. In clinical trials, elinzanetant was administered orally once daily
It is not widely prescribed
Once stable, reviews every three to six months are generally in line with good clinical practice, consistent with NICE obesity management guidance (CG189)
From a health plan perspective, lifestyle resources (e.g., fitness programs incentives, lifestyle coaching) are not as highly utilized but are the most effective for weight loss management